Dublin, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/bvwzh9/solid_tumor) has announced the addition of the "Solid Tumor Testing Market in the US 2016-2020" report to their offering.
The solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body.
The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.
Ready-to-use reagents offer many advantages such as avoiding calculation, dilution, infection, and pipetting errors; and also save time. The focus on disease treatment and gaining accurate results through sample analysis will boost the consumption of ready-to-use reagents during the forecast period.
According to the report, Proteins and genes control various functions of the body. Any defect in a particular protein or gene structure will result in the occurrence of specific disorders. The development of personalized drugs depends on the identification and study of protein and gene expressions. These personalized medicines are regulated and labeled along with a specific diagnostic test, referred to as companion diagnostic. This tailored approach facilitates better therapeutic outcomes, owing to specific screening and selection of the patient population. This factor boosts the demand for personalized medicines, which, in turn, would drive the adoption of solid tumor testing.
Further, the report states that the regulatory and reimbursement scenario in the country has been impeding market growth ever since the government introduced medical device excise tax and cuts in bundled payments, which has restricted the use of insurance by customers.
The market is divided into the following segments based on cancer types:
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other (including pancreatic cysts and thyroid nodules)
Key vendors:
- Abbott Molecular
- Agilent Technologies (Dako)
- Beckman Coulter
- Roche Diagnostics
Other prominent vendors:
- 20/20 GeneSystems
- Adaptive Biotechnologies
- Advanced Cell Diagnostics
- Affymetrix
- Agena Bioscience
- Ambry Genetics
- ApoCell
- Avant Diagnostics
- Biological Dynamics
- Boditech Med
- Becton, Dickinson and Company (BD)
- Biocare Medical
- Bio-Rad Laboratories
- Castle Biosciences
- CDx Diagnostics
- Celerus Diagnostics
- Cancer Genetics
- Caris Life Sciences
- Clarient Diagnostic Services
- DiaTech Oncology
- Enzo Biochem
- Epic Sciences
- EDP Biotech
- Eutropics Pharmaceuticals
- Fujirebio Diagnostics
- Genalyte
- Hologic
- Janssen Diagnostics
- Myriad Genetics
- Omnyx
- OxfordGene Technology
- Oncospire Genomics
- OncoCyte
- OvaGene Oncology
- Pathway Genomics
- Quest Diagnostics
- QIAGEN
- RiboMed Biotechnologies
- Sequenom
- Siemens Healthcare Diagnostics
- Thermo Fisher Scientific
- Tosoh Bioscience
- TrimGen
Key Topics Covered:
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Healthcare reform in US
- Impact of US healthcare reform on cancer testing industry
PART 06: Reimbursement and coverage: An overview
- Current scenario: Validating diagnostic tests
- Reimbursement structure in US
- Prevailing issues of reimbursement policies
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by technology
- Conventional testing
- Genetic testing
PART 09: Market segmentation by cancer type
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other
PART 10: Market drivers
- High demand for personalized medicines
- Changes in healthcare system
- Rise in demand for POC testing
- Increase in molecular testing
PART 11: Impact of drivers
PART 12: Market challenges
- Shortage of accurate cancer testing kits
- Regulatory issues
- Lack of skilled technicians
PART 13: Impact of drivers and challenges
PART 14: Market trends
- Use of bench-top mass spectrometer
- Ready-to-use reagents
PART 15: Vendor landscape
- Competitive scenario
- Key vendor analysis 2015
- Other prominent vendors
PART 16: Appendix
For more information visit http://www.researchandmarkets.com/research/bvwzh9/solid_tumor